A T-cell engaging bispecific antibody with a tumor-selective bivalent folate receptor alpha binding arm for the treatment of ovarian cancer.

Autor: Avanzino BC; Teneobio, Inc, Newark, CA, United States.; Oncology Research, Amgen Inc., Newark, CA, USA., Prabhakar K; Teneobio, Inc, Newark, CA, United States.; Oncology Research, Amgen Inc., Newark, CA, USA., Dalvi P; Teneobio, Inc, Newark, CA, United States.; Oncology Research, Amgen Inc., Newark, CA, USA., Hartstein S; Teneobio, Inc, Newark, CA, United States.; Therapeutic Discovery, Amgen Inc., Newark, CA, USA., Kehm H; Teneobio, Inc, Newark, CA, United States., Balasubramani A; Teneobio, Inc, Newark, CA, United States.; Therapeutic Discovery, Amgen Inc., Newark, CA, USA., Boudreau AA; Teneobio, Inc, Newark, CA, United States., Buelow B; Teneobio, Inc, Newark, CA, United States., Chang K; Teneobio, Inc, Newark, CA, United States., Davison LM; Teneobio, Inc, Newark, CA, United States., Iyer S; Teneobio, Inc, Newark, CA, United States., Kalwit V; Teneobio, Inc, Newark, CA, United States.; Oncology Research, Amgen Inc., Newark, CA, USA., Lewis Wilson K; Translational Safety & Bioanalytical Sciences, Amgen Inc., South San Francisco, CA, USA., Malik-Chaudhry HK; Teneobio, Inc, Newark, CA, United States.; Therapeutic Discovery, Amgen Inc., Newark, CA, USA., Pierson W; Division of Gynecologic Oncology, University of California, San Francisco, CA, USA.; University of Rochester School of Medicine and Dentistry, Rochester, NY, USA., Pineda G; Division of Gynecologic Oncology, University of California, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA., Rangaswamy US; Teneobio, Inc, Newark, CA, United States.; Oncology Research, Amgen Inc., Newark, CA, USA., Saiganesh S; Teneobio, Inc, Newark, CA, United States.; Oncology Research, Amgen Inc., Newark, CA, USA., Schellenberger U; Teneobio, Inc, Newark, CA, United States., Ugamraj HS; Teneobio, Inc, Newark, CA, United States.; Process Development, Amgen Inc., Newark, CA, USA., Yabut RD; Translational Safety & Bioanalytical Sciences, Amgen Inc., South San Francisco, CA, USA., Buelow R; Teneobio, Inc, Newark, CA, United States., Chapman J; Division of Gynecologic Oncology, University of California, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA., Trinklein ND; Teneobio, Inc, Newark, CA, United States., Harris KE; Teneobio, Inc, Newark, CA, United States.; Oncology Research, Amgen Inc., Newark, CA, USA.

Publikováno v: Oncoimmunology [Oncoimmunology] 2022 Aug 20; Vol. 11 (1), pp. 2113697. Date of Electronic Publication: 2022 Aug 20 (Print Publication: 2022).

Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release.

Autor: Dang K; Teneobio, Inc, Newark, California, USA., Castello G; Teneobio, Inc, Newark, California, USA., Clarke SC; Teneobio, Inc, Newark, California, USA., Li Y; Teneobio, Inc, Newark, California, USA., Balasubramani A; Teneobio, Inc, Newark, California, USA., Boudreau A; Teneobio, Inc, Newark, California, USA., Davison L; Teneobio, Inc, Newark, California, USA., Harris KE; Teneobio, Inc, Newark, California, USA., Pham D; Teneobio, Inc, Newark, California, USA., Sankaran P; Teneobio, Inc, Newark, California, USA., Ugamraj HS; Teneobio, Inc, Newark, California, USA., Deng R; Teneobio, Inc, Newark, California, USA., Kwek S; Department of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, California, USA., Starzinski A; Department of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, California, USA., Iyer S; Teneobio, Inc, Newark, California, USA., van Schooten W; Teneobio, Inc, Newark, California, USA., Schellenberger U; Teneobio, Inc, Newark, California, USA., Sun W; Teneobio, Inc, Newark, California, USA., Trinklein ND; Teneobio, Inc, Newark, California, USA., Buelow R; Teneobio, Inc, Newark, California, USA., Buelow B; Teneobio, Inc, Newark, California, USA., Fong L; Department of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, California, USA., Dalvi P; Teneobio, Inc, Newark, California, USA pdalvi@teneobio.com.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2021 Jun; Vol. 9 (6).

Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies.

Autor: Trinklein ND; a Teneobio, Inc ., Menlo Park , CA , USA., Pham D; a Teneobio, Inc ., Menlo Park , CA , USA., Schellenberger U; a Teneobio, Inc ., Menlo Park , CA , USA., Buelow B; a Teneobio, Inc ., Menlo Park , CA , USA., Boudreau A; a Teneobio, Inc ., Menlo Park , CA , USA., Choudhry P; b Department of Laboratory Medicine , University of California , San Francisco , CA , USA., Clarke SC; a Teneobio, Inc ., Menlo Park , CA , USA., Dang K; a Teneobio, Inc ., Menlo Park , CA , USA., Harris KE; a Teneobio, Inc ., Menlo Park , CA , USA., Iyer S; a Teneobio, Inc ., Menlo Park , CA , USA., Jorgensen B; a Teneobio, Inc ., Menlo Park , CA , USA., Pratap PP; a Teneobio, Inc ., Menlo Park , CA , USA., Rangaswamy US; a Teneobio, Inc ., Menlo Park , CA , USA., Ugamraj HS; a Teneobio, Inc ., Menlo Park , CA , USA., Vafa O; a Teneobio, Inc ., Menlo Park , CA , USA., Wiita AP; b Department of Laboratory Medicine , University of California , San Francisco , CA , USA., van Schooten W; a Teneobio, Inc ., Menlo Park , CA , USA., Buelow R; a Teneobio, Inc ., Menlo Park , CA , USA., Force Aldred S; a Teneobio, Inc ., Menlo Park , CA , USA.

Publikováno v: MAbs [MAbs] 2019 May/Jun; Vol. 11 (4), pp. 639-652. Date of Electronic Publication: 2019 Feb 20.

Sequence-Based Discovery Demonstrates That Fixed Light Chain Human Transgenic Rats Produce a Diverse Repertoire of Antigen-Specific Antibodies.

Autor: Harris KE; Teneobio, Inc., Menlo Park, CA, United States., Aldred SF; Teneobio, Inc., Menlo Park, CA, United States., Davison LM; Teneobio, Inc., Menlo Park, CA, United States., Ogana HAN; Teneobio, Inc., Menlo Park, CA, United States., Boudreau A; Teneobio, Inc., Menlo Park, CA, United States., Brüggemann M; Teneobio, Inc., Menlo Park, CA, United States., Osborn M; Teneobio, Inc., Menlo Park, CA, United States., Ma B; Teneobio, Inc., Menlo Park, CA, United States., Buelow B; Teneobio, Inc., Menlo Park, CA, United States., Clarke SC; Teneobio, Inc., Menlo Park, CA, United States., Dang KH; Teneobio, Inc., Menlo Park, CA, United States., Iyer S; Teneobio, Inc., Menlo Park, CA, United States., Jorgensen B; Teneobio, Inc., Menlo Park, CA, United States., Pham DT; Teneobio, Inc., Menlo Park, CA, United States., Pratap PP; Teneobio, Inc., Menlo Park, CA, United States., Rangaswamy US; Teneobio, Inc., Menlo Park, CA, United States., Schellenberger U; Teneobio, Inc., Menlo Park, CA, United States., van Schooten WC; Teneobio, Inc., Menlo Park, CA, United States., Ugamraj HS; Teneobio, Inc., Menlo Park, CA, United States., Vafa O; Teneobio, Inc., Menlo Park, CA, United States., Buelow R; Teneobio, Inc., Menlo Park, CA, United States., Trinklein ND; Teneobio, Inc., Menlo Park, CA, United States.

Publikováno v: Frontiers in immunology [Front Immunol] 2018 Apr 24; Vol. 9, pp. 889. Date of Electronic Publication: 2018 Apr 24 (Print Publication: 2018).